Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia
出版年份 2020 全文链接
标题
Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia
作者
关键词
-
出版物
Science Advances
Volume 6, Issue 35, Pages eaaz9890
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2020-08-27
DOI
10.1126/sciadv.aaz9890
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
- (2019) Steven A. Kliewer et al. Cell Metabolism
- Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes
- (2018) Megan E Capozzi et al. ENDOCRINE REVIEWS
- Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action
- (2018) Caslin A. Gilroy et al. JOURNAL OF CONTROLLED RELEASE
- Peptide-based multi-agonists: a new paradigm in metabolic pharmacology
- (2018) Sara J. Brandt et al. JOURNAL OF INTERNAL MEDICINE
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
- (2018) Christoffer Clemmensen et al. Nature Reviews Endocrinology
- One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
- (2017) Kelli M. Luginbuhl et al. Nature Biomedical Engineering
- iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy
- (2016) Lydia Lynch et al. Cell Metabolism
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Fibroblast growth factor 21 night watch: advances and uncertainties in the field
- (2016) A. Kharitonenkov et al. JOURNAL OF INTERNAL MEDICINE
- Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries
- (2016) Roman Mathaes et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
- (2016) Ji-Hee Ha et al. Frontiers in Immunology
- Time to and factors associated with insulin initiation in patients with type 2 diabetes mellitus
- (2015) Jorge Enrique Machado-Alba et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
- (2015) Darleen A. Sandoval et al. PHYSIOLOGICAL REVIEWS
- FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
- (2015) Alexei Kharitonenkov et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
- (2013) K. M. Habegger et al. DIABETES
- A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection
- (2013) M. Amiram et al. JOURNAL OF CONTROLLED RELEASE
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Recursive Directional Ligation by Plasmid Reconstruction Allows Rapid and Seamless Cloning of Oligomeric Genes
- (2010) Jonathan R. McDaniel et al. BIOMACROMOLECULES
- Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes
- (2010) A. Ringborg et al. DIABETES & METABOLISM
- Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice
- (2009) Michael J. Riedel et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Different roles of N- and C- termini in the functional activity of FGF21
- (2009) Radmila Micanovic et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started